Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4739886 | 1.00 | FOLH1 (0.55) | FOLH1SRCCTSLCTSBCTSS | |
| SCHEMBL4598877 | 0.87 | FOLH1 (0.57) | FOLH1SLC6A5 | |
| SCHEMBL4598870 | 0.87 | FOLH1 (0.57) | FOLH1SLC6A5 | |
| SCHEMBL4738193 | 0.86 | FOLH1 (0.62) | FOLH1C3AR1 | |
| SCHEMBL4739090 | 0.86 | FOLH1 (0.46) | FOLH1C3AR1ERAP2LNPEPMEP1B | |
| SCHEMBL4739082 | 0.86 | FOLH1 (0.46) | FOLH1C3AR1ERAP2LNPEPMEP1B | |
| SCHEMBL4738184 | 0.86 | FOLH1 (0.62) | FOLH1C3AR1 | |
| SCHEMBL4599885 | 0.86 | TGM2 (0.48) | FOLH1 | |
| SCHEMBL4599882 | 0.86 | TGM2 (0.48) | FOLH1 | |
| SCHEMBL4738209 | 0.84 | MEN1 (0.51) | C3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| WO-2008080223-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-10 | — | — | WO | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | FOLH1 771/4885SRC 4612/4885CTSL 922/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | FOLH1 1486/4885SRC 2458/4885CTSL 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.